It has been shown that erythropoietin β and iron treatment has a beneficial effect on the levels of antibodies against oxidized LDL and on serum PON1 activity in pre dialysis patients with chronic renal disease and anemia [76]. The gene discussed is PON1; the disease is chronic kidney disease.